Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Deutetrabenazine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,341Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aurobindo`s Generics Deutetrabenazine Receives Approval in US
    Aurobindo`s Generics Deutetrabenazine Receives Approval in US

    26 Dec 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215971

    FDA
    26 Dec 2024
    Share Share
    Teva's IMPACT-TD Real-World Data On Tardive Dyskinesia At Psych Congress
    Teva's IMPACT-TD Real-World Data On Tardive Dyskinesia At Psych Congress

    01 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240601407405/en

    BUSINESSWIRE
    01 Jun 2024
    Share Share
    Teva's AUSTEDO® XR Approved As Once-Daily ADHD Treatment Option
    Teva's AUSTEDO® XR Approved As Once-Daily ADHD Treatment Option

    29 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240425312754/en

    BUSINESSWIRE
    29 May 2024
    Share Share
    Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024
    Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024

    08 May 2024

    // PRESS RELEASE

    https://www.tevapharm.com/news-and-media/latest-news/teva-reports-first-quarter-2024-financial-results-and-reaffirms-2024-financial-outlook/

    PRESS RELEASE
    08 May 2024
    Share Share
    Teva: AUSTEDO® RWE Confirms Efficacy, Satisfaction In HD Chorea
    Teva: AUSTEDO® RWE Confirms Efficacy, Satisfaction In HD Chorea

    16 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240416126685/en

    BUSINESSWIRE
    16 Apr 2024
    Share Share
    Teva to Present New Data Supporting Safety of AUSTEDO Tablets
    Teva to Present New Data Supporting Safety of AUSTEDO Tablets

    02 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231102180929/en

    BUSINESSWIRE
    02 Nov 2023
    Share Share